Aspen Neuroscience raises $141M in Nasdaq IPO for Parkinson's cell therapy
What's the deal? Aspen Neuroscience, a San Diego clinical-stage biotech developing autologous cell therapies for Parkinson's disease, priced its initial public offering at $15 per share, raising roughly $140.6 million before expenses. The company sold 9,375,000 shares, with trading set to begin on the Nasdaq Global Select Market under the ticker "ASPE" on October 30, 2026.
The details: Aspen priced at the bottom of its $15–$17 range. It also granted underwriters a 30-day option to buy up to 1,406,250 additional shares. Leerink PartnersDealroom has a profile for this one. Try Dealroom →, Piper SandlerDealroom has a profile for this one. Try Dealroom →, Stifel, UBS Investment BankDealroom has a profile for this one. Try Dealroom →, and Oppenheimer & Co.Dealroom has a profile for this one. Try Dealroom → acted as joint bookrunning managers.
Why now? The listing lands amid a pickup in biotech IPOs, with more than half a dozen firms going public in New York since September, according to Reuters. Investor demand remains selective, however, as higher rates weigh on companies still years from revenue.
What's the endgame? Aspen's lead candidate, sasineprocel, is an investigational single-dose cell therapy for Parkinson's. The capital funds a long development path: the therapy is still in Phase 1/2a, with just 15 patients dosed by June, and the company expects to start a Phase 3 trial in the second half of 2027.
What could go wrong? The pricing at the low end of its range signals cautious demand. As a clinical-stage company, Aspen's prospects hinge on trial outcomes for a single lead candidate, leaving the stock exposed to the risks of early-stage results.
The signal: The offering shows the biotech IPO window is open again, but on tighter terms. Aspen's RMAT designation and progress toward a scalable formulation are encouraging, yet the small clinical evidence base means the raise funds ambition — not proof of efficacy.
Read more: pr.southjordanjournal.com
Image credit: Generated with Gemini
